Sichuan Biokin Pharmaceutical Co., Ltd.SSE: 688506

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of T-Bren (HER2 ADC) in the List of Breakthrough Therapy Designations for Patients with HER2-Expressing Locally Advanced or Metastatic Biliary Tract Cancer Who Have Failed Platinum-based Chemotherapy

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688506 ·

On 6ix: 6ix.com/news/688506sichuan-biokin-pharmaceutical-co-ltdannouncement-on-voluntary-disclosure-of-the-inclusion-of-t-bren-her2-adc-in-the-list-of-breakthrough-therapy-designations-for-patients-with-her2-expressing-locally-advanced-or-metastatic-biliary-tract-cancer-who-have-failed-platinum-based-chemotherapy

Announcement on Voluntary Disclosure of the Inclusion of T-Bren (HER2 ADC) in the List of Breakthrough Therapy Designations for Patients with HER2-Expressing Locally Advanced or Metastatic Biliary Tract Cancer Who Have Failed Platinum-based Chemotherapy

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

View original source (Shanghai Stock Exchange)Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from Sichuan Biokin Pharmaceutical

Later from Sichuan Biokin Pharmaceutical

All Sichuan Biokin Pharmaceutical news releases